SCHEMBL6162731

SCHEMBL6162731

O=C(NCc1cccs1)c1c[nH]c2c(c1=O)CCCC2

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 12/20 0.58
ALDH1A1 P00352 7/20 0.58
KMT2A Q03164 6/20 0.58
MEN1 O00255 5/20 0.58
RAB9A P51151 5/20 0.55
TP53 P04637 3/20 0.55
LMNA P02545 2/20 0.55
MAPK1 P28482 1/20 0.55
SMN1; SMN2 Q16637 3/20 0.53
NPC1 O15118 3/20 0.53
POLB P06746 3/20 0.53
HSD17B10 Q99714 2/20 0.53
CYP1A2 P05177 2/20 0.53
CYP3A4 P08684 2/20 0.53
CYP2D6 P10635 2/20 0.53
CYP2C9 P11712 2/20 0.53
CYP2C19 P33261 2/20 0.53
MAPK10 P53779 1/20 0.53
TSHR P16473 3/20 0.52
HTT P42858 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6162507 0.81 ADORA2A (0.55) HPGDALDH1A1KMT2ARAB9ALMNA
SCHEMBL6161725 0.80 MAPT (0.41) HPGDALDH1A1KMT2AMEN1RAB9A
SCHEMBL6162671 0.80 HPGD (0.55) HPGDALDH1A1KMT2ARAB9ALMNA
SCHEMBL6160996 0.79 ADORA2A (0.55) HPGDALDH1A1KMT2ARAB9ASMN1; SMN2
SCHEMBL6161944 0.78 ADORA2A (0.55) ALDH1A1KMT2AMEN1RAB9ALMNA
SCHEMBL6160803 0.78 ADORA2A (0.55) ALDH1A1KMT2AMEN1POLBMAPT
SCHEMBL6161991 0.78 ADORA2A (0.57) HPGDALDH1A1TP53LMNASMN1; SMN2
SCHEMBL6162255 0.78 MAPT (0.41) HPGDALDH1A1KMT2AMEN1RAB9A
SCHEMBL6162370 0.77 GABRP (0.46) HPGDALDH1A1KMT2AMEN1RAB9A
SCHEMBL6162307 0.77 ADORA2A (0.54) HPGDALDH1A1KMT2AMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1056724-B1 SUBSTITUTED CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORP (US) 2005-05-25 EP claimed
US-6194427-B1 BRAIN DISORDERS; PSYCHOLOGICAL DISORDERS; SLEEP DISORDERS; ANTICONVULSANTS NEUROGEN CORPORATION 2001-02-27 US claimed
EP-1056724-A2 SUBSTITUTED CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 2000-12-06 EP claimed
WO-1999043661-A2 SUBSTITUTED CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 1999-09-02 WO claimed
EP-1056724-B1 SUBSTITUTED CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORP (US) 2005-05-25 EP disclosed
US-6448259-B1 CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; AGONISTS, ANTAGONISTS OR INVERSE AGONISTS FOR GAMMA AMINOBUTYRIC ACID BINDING SITE, THE BENZODIAZEPINE RECEPTOR; ANXIETY, SLEEP AND SEIZURE DISORDERS SEDATIVE, ANXIOLYTIC AND ANTICONVULSANT ACTIVITY NEUROGEN CORPORATION 2002-09-10 US disclosed
US-6194427-B1 BRAIN DISORDERS; PSYCHOLOGICAL DISORDERS; SLEEP DISORDERS; ANTICONVULSANTS NEUROGEN CORPORATION 2001-02-27 US disclosed